Felpin

Quick links to important sections

Felpin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Felpin

Property Description
Active Ingredient Felodipine
Form Extended-release (ER) oral tablets
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
General Purpose Managing elevated systemic blood pressure
Origin Synthetic compound

1. Defining Felpin: Active Ingredient and Class

Felpin is a prescription-only, synthetic pharmaceutical agent containing the active substance Felodipine. This compound is structurally categorized as a dihydropyridine derivative and belongs to the major pharmacological group known as calcium channel blockers (CCBs).

Felodipine is clinically recognized as an established antihypertensive agent. This confirms its foundational role in the general modulation of pressure within the circulatory system, which is a core requirement for its therapeutic profile.

2. Felpin’s Form and Key Mechanism

The active ingredient is provided for the oral route of administration typically as an extended-release (ER) oral tablet. This specialized formulation ensures the Felodipine is released gradually, maintaining a consistent action over a prolonged period. The drug functions as a highly selective calcium channel antagonist, blocking the entry of calcium ions (Ca^++) into the smooth muscle cells that line the arteries.

Its high selectivity for vascular tissue over cardiac tissue confirms the medication is specifically designed to maximize its relaxing effect on the peripheral blood vessels.

3. General Therapeutic Purpose and Action

The fundamental goal of this medication is to reduce the resistance against which the heart must pump blood. By preventing calcium influx, Felodipine inhibits the contraction of vascular smooth muscle, leading to the relaxation and widening of blood vessels (vasodilation). This physical effect directly results in a decrease in peripheral vascular resistance, which serves as the general benefit of the drug: it assists in the maintenance of healthy circulatory function and reduces the overall cardiovascular workload.

Regulatory References

  1. United States National Library of Medicine (MedlinePlus)

What side effects are possible with Felpin?

Possible Side Effects and Safety Information

The information regarding the safety profile of Felpin (Felodipine) is based strictly on officially documented adverse reactions and safety statements from government regulatory authorities.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency, as reported in regulatory documents and clinical trials:

Classification Adverse Reactions
Very Common Peripheral edema, Headache
Common Flushing, Fatigue
Uncommon Palpitations, Nausea, Dizziness, Rash, Abdominal pain
Rare Gingival hyperplasia, Urticaria, Photosensitivity reaction

These effects are grouped into categories such as Vascular disorders, Nervous system disorders, and Gastrointestinal disorders, reflecting the system-organ class affected.


Serious Adverse Reactions and Restrictions

Official labeling documents the potential for certain serious events, though they are rare. These include a paradoxical worsening of angina pectoris or myocardial infarction in susceptible individuals, and severe hypersensitivity reactions such as Angioedema.

Safety Restrictions: Felpin is contraindicated in patients with severe hepatic impairment due to reduced drug clearance leading to elevated plasma concentrations. Safety notes also advise caution in older adults due to increased plasma concentrations and potential for higher incidence of dose-dependent effects.

Headache and flushing are often transient, being more common at the initiation of therapy or following a dose increase. Good dental hygiene is noted to decrease the incidence and severity of gingival hyperplasia.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Felpin (Felodipine) is defined by officially documented regulatory sources as a condition resulting in excessive peripheral vasodilatation. This critical physiological effect leads to the key manifestations of marked hypotension (severely low blood pressure) and is often accompanied by bradycardia (a pathologically slow heart rate). Less severe clinical signs that are documented in the labeling include a light-headed feeling, warmth or tingling, and pronounced flushing of the face and upper body.

Overdose with these primary cardiovascular symptoms is classified by regulatory authorities as a potentially life-threatening event. Regulatory guidance explicitly mandates that individuals who suspect an overdose must immediately seek emergency medical attention and contact the Poison Help line or emergency services.

Management procedures detailed in the official product labeling are strictly symptomatic and supportive, as no specific antidote is known. Officially described initial measures may involve the administration of activated charcoal or gastric lavage, if medically appropriate and performed within the correct timeframe. Severe hypotension is managed by positioning the patient supine with legs elevated. In cases of persistent bradycardia, specific interventions such as intravenous administration of Atropine or plasma volume expansion using agents like saline or glucose may be required under professional institutional monitoring.

Therapeutic Uses of Felpin

What Felpin Treats: Main Uses and Benefits

Felpin (Felodipine) is commonly used for managing conditions characterized by periods of heightened symptoms that are associated with systemic imbalance and heightened physiological activity. Its core function is applied in addressing high blood pressure and stable angina, and may be part of symptomatic management in contexts involving chronic conditions.

The medication's primary therapeutic benefit is sustained blood pressure control and supporting relief from ischemia-related discomfort. It is considered relevant for use in conditions including essential hypertension and chronic stable angina pectoris.


Therapeutic Contexts and Patient Benefit

Felpin's central application is in the long-term management of elevated arterial pressure, a systemic imbalance. This use supports addressing symptoms related to systemic imbalance that stem from high peripheral resistance. In situations where patients experience chest discomfort, this medication may assist with managing symptoms related to physical discomfort such as ischemia-related chest discomfort, contributing to improved comfort and assisting with maintaining functional stability during periods of heightened symptoms.

“The medication is generally applied to help manage mild-to-moderate cases as initial management, and may be part of symptomatic management in regimens for more severe or resistant hypertension.”

This medication is commonly used to help with blood pressure control in individuals who have hypertension alongside other chronic conditions, such as Type 2 Diabetes Mellitus, or in older adults requiring treatment for isolated systolic hypertension. This application assists with maintaining functional stability and supports the general well-being of patients in scenarios where additional management of discomfort is required.


Quick Fact: Relief for Systemic Imbalance

Felpin plays a role in managing conditions presenting with systemic or localized discomfort, specifically by supporting the long-term control of high arterial pressure, a factor relevant to cardiovascular health.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Felpin — Official Regulatory Information

Felpin is approved for use in the general adult population (18 years and over). However, government regulatory documents define several high-risk groups for whom use is prohibited or restricted.

Contraindicated Populations (Must Not Use)

Felpin is absolutely contraindicated for patients with:

  • Known hypersensitivity to Felodipine or any other dihydropyridine derivative.
  • Pregnancy or Uncompensated Heart Failure (Decompensated heart failure).
  • Severe acute cardiac conditions, including Acute Myocardial Infarction, Unstable Angina Pectoris, Haemodynamically Significant Cardiac Valvular Obstruction, or Dynamic Cardiac Outflow Obstruction.

Age and Condition-Based Restrictions

Population Group Regulatory Status
Pediatric Population (under 18) Use Not Established (Not Recommended)
Older Adults/Geriatric Patients Restricted Use: Treatment must begin with the lowest available dose.
Impaired Hepatic Function Restricted Use: Requires a reduction in the initial dose due to increased plasma concentrations.
Impaired Renal Function Use Allowed: No dose adjustment is generally needed.
Lactating/Breastfeeding Women Not Recommended due to insufficient data on potential effects on the infant.

The official profile classifies eligibility based on age, reproductive status, and the presence of specific comorbidities, such as severe cardiac or liver conditions, defining clear boundaries for use under regulatory guidelines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Felpin (Felodipine) is a sensitive substrate primarily cleared from the body by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic pathway forms the basis for most documented drug-drug and drug-product interactions, which are formally outlined in regulatory prescribing information.

Pharmacokinetic Interactions (Exposure Modification)

Official labeling describes several combinations that significantly alter Felpin's plasma concentration:

  • Increased Exposure (CYP3A4 Inhibition): Co-administration with potent CYP3A4 inhibitors, such as Itraconazole and Ketoconazole, is classified as a combination to be avoided or contraindicated. This pharmacokinetic interaction can raise Felpin levels by eight-fold or more, requiring restriction. Other inhibitors like Erythromycin and Cimetidine also increase exposure.
  • Decreased Exposure (CYP3A4 Induction): Co-administration with potent CYP3A4 inducers, including Rifampicin, Phenytoin, Carbamazepine, and the herbal product St. John’s wort, reduces Felpin plasma concentrations. This may reduce its expected effectiveness.

Other Documented Interactions

Interaction Type Interacting Substance/Product Regulatory Statement
Product Interference Grapefruit/Grapefruit Juice Consumption is restricted due to a documented increase in Felpin exposure and C max
Pharmacodynamic Other Antihypertensive Agents Co-administration may result in an additive blood pressure lowering effect
Transporter Effect Tacrolimus Felpin may increase Tacrolimus blood concentration, requiring monitoring
Population Note Hepatic Impairment Reduced clearance in liver disease may heighten the severity of interactions that increase exposure

Mechanism of Action

How Felpin Works: Pharmacodynamic Mechanism

Felpin's mechanism involves non-competitive antagonism against the voltage-gated L-type calcium channels (CaV1.x) primarily located on the membranes of peripheral resistance arteries. By binding to these channels, the molecule restricts the influx of extracellular calcium ions (Ca^++) into the smooth muscle cell cytoplasm. This molecular event directly interrupts the process of excitation-contraction coupling by limiting the availability of calcium needed for Myosin Light-Chain Kinase (MLCK) activation.

The resulting inhibition of the smooth muscle contraction cycle leads to widespread arteriolar relaxation (vasodilation) at the tissue level. This functional change produces the primary system-level physiological consequence: a direct and measurable reduction in Peripheral Vascular Resistance (PVR). The prolonged, steady blockade required for this continuous effect is supported by the extended-release formulation.

The reduction in PVR can trigger the baroreceptor reflex, a physiological feedback mechanism that responds by increasing the heart rate (reflex tachycardia). This reflex partially offsets the primary vascular effect, representing a key constraint of the mechanism.

Dosage and Administration Information

How to Use Felpin: Official Administration Guidelines

Felpin (Felodipine) is approved for oral administration as an extended-release (ER) tablet in strengths including 2.5 mg, 5 mg, and 10 mg. The medication is intended for chronic, long-term use, administered as a once-daily regimen, preferably taken in the morning.


Dosing and Intake Conditions

The standard initial daily dose for adults is typically 5 mg. For specific populations, such as older adults or individuals with hepatic (liver) impairment, instructions specify starting with a lower initial dose of 2.5 mg once daily. Dose adjustments are gradual; healthcare providers are instructed to wait at least two weeks between changes to assess the patient’s response. The maximum recommended daily dose is 10 mg.

The administration of the tablet requires specific procedural adherence: it must be swallowed whole and must not be crushed, split, or chewed, as this compromises the prolonged-release properties. Felpin can be taken either without food or with a light meal (low in fat), but consumption of grapefruit or grapefruit juice must be strictly avoided. In the event that a dose is missed, the guidance is to skip the forgotten dose and resume the normal schedule with the next dose at the usual time; doubling the dose to compensate is explicitly not recommended. For patients with renal (kidney) impairment, no specific dose adjustment is generally required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Felpin

Evidence for Use in Essential Hypertension

The evidence for Felpin was studied for elevated systemic blood pressure primarily through numerous randomized controlled trials (RCTs). These studies compared the medicine against inactive substances or other established treatments. The main findings describe patterns observed where blood pressure measurements were observed to be different between the groups receiving the medicine and the comparison groups over defined time intervals.

Long-term studies have explored the medicine's association with major cardiovascular outcomes. Some large-scale trials reported data showing patterns related to incidence rates of events like stroke that varied between groups where the medicine was studied as part of a regimen. Evidence is limited regarding the degree to which these outcomes are influenced by factors beyond the measured blood pressure changes.


Evidence for Use in Chronic Stable Angina Pectoris

The research base for Felpin was studied for chronic stable angina pectoris and consists of short-term, double-blind trials. Studies explored patient-reported outcomes describing perceived discomfort, such as the weekly frequency of discomfort episodes and the use of supplemental medication. Trials observed patterns where the frequency of episodes and supplemental medication use varied between the study groups in the short term.

Research highlights changes measured during the study period, such as patterns observed in the time until the onset of ischemic signs during physical activity. Evidence is limited regarding the long-term study of major cardiovascular outcomes specifically for angina patients, as research primarily focuses on short-term symptom relief and functional measures.


Evidence in Special Populations and Uncertainties

Specific research has been studied in particular patient groups, notably older adults with Isolated Systolic Hypertension (ISH). Findings indicate that measurements of systolic blood pressure (SBP) and structural outcomes were observed to vary between the groups receiving the medicine and those receiving placebo in these older adult cohorts over the one-year study.

In the supplementary context of Chronic Heart Failure (as add-on therapy), large randomized trials were conducted. Evidence is limited for long-term outcomes related to this condition. The findings were mixed, and the research did not describe patterns of sustained, long-term difference for primary endpoints, such as mortality, in this population. Data for other groups, such as children or pregnant populations, remain insufficient. Overall, research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Felpin (FAQ)

Q: What are the generally known uses of Felpin?

Official product information states that Felpin is approved to treat two main conditions: elevated systemic blood pressure (hypertension) and chronic stable angina pectoris. These are the conditions defined in the official prescribing information.


Q: What is the difference between the brand name Felpin and its generic form?

The generic version contains the exact same active ingredient, Felodipine, as the brand-name product. Regulatory agencies require that a generic drug must be bioequivalent to the brand-name drug, meaning it must be shown to perform comparably in the body.


Q: Does Felpin commonly cause side effects like drowsiness or fatigue?

Official safety information indicates that fatigue is a common side effect of Felpin. Other nervous system effects, such as dizziness or somnolence (drowsiness), have also been reported, though less frequently.


Q: What are the most frequently reported side effects of Felpin in clinical summaries?

According to official regulatory documents, the most frequently reported side effects are categorized as Very Common. These include peripheral edema (which is typically swelling in the ankles or feet) and headache.


Q: Does Felpin have the potential to cause weight changes, such as gain or loss?

Safety information notes that certain changes, specifically unusual or rapid weight gain, have been reported as potential side effects. This type of weight increase is often related to the fluid retention that causes peripheral edema.


Q: Is stomach upset a typical experience when first starting Felpin?

Gastrointestinal issues that are often referred to as 'stomach upset' are commonly reported. Official safety information categorizes side effects such as nausea and indigestion (dyspepsia) as common, which may occur when beginning treatment.


Q: How will a person generally know if Felpin is working for their condition?

For the treatment of high blood pressure, effectiveness is often characterized by changes in blood pressure measurements, which are assessed by a healthcare provider. If used for angina, effectiveness is often related to observing a reduced frequency of chest pain episodes.


Q: Why might a doctor prescribe Felpin instead of a different, similar drug?

Felpin is a type of calcium channel blocker that is known to be highly selective for blood vessels. Official pharmacological data indicates that it shows a higher selectivity for vascular tissue compared to cardiac tissue than some other drugs in its class.


Q: Why do some patients online report feeling worse before they feel better on Felpin?

Side effects such as headache and flushing are often transient, meaning they are short-lived. Regulatory information notes that these effects tend to be more common when a person is initiating the medication or following a dose increase.


Q: Are there any known long-term side effects associated with Felpin use?

While the drug is intended for long-term use, one rare but noted potential effect with prolonged use is gingival hyperplasia, which is a swelling of the gums. Official safety notes state that maintaining good dental hygiene may help reduce the incidence of this condition.


Q: What are the signs of a non-severe reaction to Felpin?

According to official safety information, non-severe reactions can include symptoms like headache, flushing (reddening of the face or neck), nausea, and peripheral edema (which appears as swelling in the arms, hands, or lower legs).


Q: What happens if Felpin is used for a long period of time?

Felpin is specifically approved and intended for chronic, long-term use for its approved conditions. As with any long-term medication, continued use is generally associated with periodic monitoring by a healthcare provider to assess both safety and continued effectiveness.


Q: What is the expected duration of treatment with Felpin?

As a treatment for chronic conditions like hypertension or angina, Felpin is generally intended for long-term use as part of an ongoing treatment plan. The duration of therapy is typically determined by the prescribing physician based on the individual's condition and response.


Q: How long does Felpin typically stay in a person's system after the last intake?

The medication is formulated for once-daily dosing. Official pharmacological data indicates that the mean terminal elimination half-life for the extended-release formulation typically ranges from approximately 11 to 28 hours in adults.


Q: Can Felpin be taken at the same time as common over-the-counter (OTC) pain relievers?

Regulatory documents note that co-administration with a class of pain relievers called Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes drugs like ibuprofen, may reduce the blood pressure-lowering effect of Felpin. It is important to note that such combinations are typically monitored by a healthcare provider.


Q: Are there any common vitamins or herbal supplements that may have an interaction with Felpin?

The herbal product St. John’s wort is officially noted to potentially reduce the effectiveness of Felpin. Some authoritative drug information also suggests that multivitamins with minerals may decrease its overall effects.


Q: Is it safe to consume alcohol while taking Felpin?

Official safety warnings indicate that consuming alcohol while taking Felpin may intensify the blood pressure-lowering effect of the medication. This additive effect can potentially result in symptoms such as dizziness or light-headedness.


Q: Is Felpin considered a controlled substance in the US or other countries?

Felpin (Felodipine) is not classified as a controlled substance by regulatory agencies in the United States.


Q: What non-prescription items should generally be avoided while taking Felpin?

Official warnings state that consumption of grapefruit or grapefruit juice is restricted due to interaction risk. Other non-prescription items to be cautious about include the herbal product St. John’s wort and certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs).


Q: Is Felpin known to be addictive or habit-forming?

Since Felpin is not classified as a controlled substance by regulatory bodies, it is not known to be addictive or habit-forming.


Q: Can I stop taking Felpin suddenly without professional guidance?

Abruptly stopping blood pressure medication is generally not advised. Official warnings note that stopping the drug suddenly has been associated with a potential worsening of symptoms, especially in individuals using it for angina.


Q: Where can I find the official regulatory information about Felpin from government sources?

Official, authoritative information can be accessed directly through governmental sources. Key sources include the FDA (Food and Drug Administration) Prescribing Information and the EMA (European Medicines Agency) Summary of Product Characteristics (SmPC).


Q: When was Felpin first approved by the FDA or other major regulatory body?

Felpin (Felodipine) was approved for use in the United States by the FDA (Food and Drug Administration) in 1991.


Q: Does Felpin carry any specific warnings related to driving or operating machinery?

Yes, due to the potential for side effects like dizziness, drowsiness, or low blood pressure, regulatory warnings suggest patients refrain from driving or operating hazardous machinery until they are aware of how the medication affects their coordination and concentration.

How should Felpin be stored and disposed of?

How to Store and Dispose of Felpin?

Felpin (Felodipine extended-release tablets) must be stored under specific environmental and container conditions as defined by regulatory labeling.

Storage Conditions

Requirement Specifics
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Keep from freezing.
Environment Protect from light and excess moisture and heat.
Container Keep in the original container and keep the container tightly closed.
Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Felpin must be discarded according to local requirements and state legislation. The medication should not be flushed down the toilet or poured down drains to prevent environmental contamination, as it is toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Felpin found in:

A-Z Index: